Marijana Tadic1, Cesare Cuspidi2, Dagmara Hering3, Lucia Venneri4, Oleksandr Danylenko4. 1. Cardiology department, University Clinical Hospital Centre "Dr. Dragisa Misovic", Belgrade, Serbia. 2. Clinical Research Unit, University of Milan-Bicocca and Italian Institute for Auxology, Meda, Italy. 3. Dobney Hypertension Centre, School of Medicine and Pharmacology-Royal Perth, Hospital Unit, The University of Western Australia, Perth, Australia. 4. Department of Echocardiography, Royal Brompton Hospital, London, United Kingdom.
Abstract
BACKGROUND: A large number of chemotherapy-induced cardiovascular complications were discovered in studies over the last several decades. The focus of the majority of these studies was left ventricular (LV) remodeling. The aim of this article was to provide a comprehensive overview of potential mechanisms of chemotherapy-induced right ventricular (RV) remodeling and summarize clinical studies on this topic. HYPOTHESIS: Chemotherapy induces RV structural, functional, and mechanical changes. METHODS: We searched PubMed, MEDLINE, Ovid and Embase databases for studies published from January 1990 up to September 2016 in the English language using the following keyword "chemotherapy," "heart," "right ventricle," "anthracyclines," and "trastuzumab." RESULTS: The existing research show that RV remodeling occurs simultaneously with LV remodeling, which is why RV remodeling should not be neglected in the overall cardiac assessment of patients treated with chemotherapy, and especially those protocols that involve anthracyclines and trastuzumab. Investigations showed that these agents could significantly impact RV structure, function, and mechanics. These medications induce fibrosis of the RV myocardium, RV dilatation, decline in RV systolic function, worsening of its diastolic function, and finally impairment of RV mechanics (strain). The mechanisms of chemotherapy-induced RV remodeling are still not entirely clear, but it is considered that direct destructive influence of chemotherapy on myocardium, oxidative stress, endothelial dysfunction, and negative impact on pulmonary circulation could significantly contribute to RV impairment. CONCLUSIONS: Chemotherapy induces the impairment of RV structure, function, and mechanics by different complex mechanisms.
BACKGROUND: A large number of chemotherapy-induced cardiovascular complications were discovered in studies over the last several decades. The focus of the majority of these studies was left ventricular (LV) remodeling. The aim of this article was to provide a comprehensive overview of potential mechanisms of chemotherapy-induced right ventricular (RV) remodeling and summarize clinical studies on this topic. HYPOTHESIS: Chemotherapy induces RV structural, functional, and mechanical changes. METHODS: We searched PubMed, MEDLINE, Ovid and Embase databases for studies published from January 1990 up to September 2016 in the English language using the following keyword "chemotherapy," "heart," "right ventricle," "anthracyclines," and "trastuzumab." RESULTS: The existing research show that RV remodeling occurs simultaneously with LV remodeling, which is why RV remodeling should not be neglected in the overall cardiac assessment of patients treated with chemotherapy, and especially those protocols that involve anthracyclines and trastuzumab. Investigations showed that these agents could significantly impact RV structure, function, and mechanics. These medications induce fibrosis of the RV myocardium, RV dilatation, decline in RV systolic function, worsening of its diastolic function, and finally impairment of RV mechanics (strain). The mechanisms of chemotherapy-induced RV remodeling are still not entirely clear, but it is considered that direct destructive influence of chemotherapy on myocardium, oxidative stress, endothelial dysfunction, and negative impact on pulmonary circulation could significantly contribute to RV impairment. CONCLUSIONS: Chemotherapy induces the impairment of RV structure, function, and mechanics by different complex mechanisms.
Authors: Suchi Grover; Darryl P Leong; Adhiraj Chakrabarty; Lucas Joerg; Dusan Kotasek; Kerry Cheong; Rohit Joshi; Majo X Joseph; Carmine DePasquale; Bogda Koczwara; Joseph B Selvanayagam Journal: Int J Cardiol Date: 2013-08-02 Impact factor: 4.164
Authors: Stefan A Lange; Bernd Ebner; Astrid Wess; Matthias Kögel; Mieczyslaw Gajda; Thomas Hitschold; Jens Jung Journal: Clin Res Cardiol Date: 2012-01-17 Impact factor: 5.460
Authors: Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter Journal: Eur Heart J Date: 2016-08-26 Impact factor: 29.983
Authors: Anna Calleja; Frédéric Poulin; Ciril Khorolsky; Masoud Shariat; Philippe L Bedard; Eitan Amir; Harry Rakowski; Michael McDonald; Diego Delgado; Paaladinesh Thavendiranathan Journal: J Oncol Date: 2015-08-03 Impact factor: 4.375
Authors: Andreas Seraphim; Mark Westwood; Anish N Bhuva; Tom Crake; James C Moon; Leon J Menezes; Guy Lloyd; Arjun K Ghosh; Sarah Slater; Heather Oakervee; Charlotte H Manisty Journal: Curr Treat Options Oncol Date: 2019-08-08
Authors: Rebecca Dobson; Arjun K Ghosh; Bonnie Ky; Tom Marwick; Martin Stout; Allan Harkness; Rick Steeds; Shaun Robinson; David Oxborough; David Adlam; Susannah Stanway; Bushra Rana; Thomas Ingram; Liam Ring; Stuart Rosen; Chris Plummer; Charlotte Manisty; Mark Harbinson; Vishal Sharma; Keith Pearce; Alexander R Lyon; Daniel X Augustine Journal: Echo Res Pract Date: 2021-03-31